You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
愛博醫療(688050.SH)一季度淨利潤預增52.75%到72.19%
格隆匯 03-30 15:42

格隆匯3月30日丨愛博醫療(688050.SH)公佈,預計2022年第一季度營業收入為1.27億元到1.36億元,與上年同期(法定披露數據)相比,將增加4259.06萬元到5159.06萬元,同比增加50.46%到61.12%。

預計2022年第一季度實現歸屬於母公司所有者的淨利潤為5500萬元到6200萬元,與上年同期(法定披露數據)相比,將增加1899.28萬元到2599.28萬元,同比增加52.75%到72.19%。

2022年第一季度淨利潤增長主要源於公司核心普諾明等系列人工晶體和普諾瞳角膜塑形銷量持續保持較快增長,營業收入增加。

2022季度國內新冠疫情影響區域較廣、時間較長導致白內障和近視患者就診量減少一定程度上影響了公司業務增速

2022第一季度經常性損益較上年同期有一定增長主要公司利用閒置資金購買理財產品獲取的投資收益以及當期收到創新醫療器械補貼政府補助加所致

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account